

UNIVERSITY OF MIAMI
Curriculum Vitae

1. **Date:** Jan 26, 2018

I. Personal

2. **Name:** Kalyan Ram Bhamidimarri, MD, MPH

3. **Home Phone:** NA

4. **Office Phone:** (305) 243-3333

5. **Home Address:** NA

6. **Current Academic Rank:** Associate Professor of Clinical Medicine

a. Current Track of Appointment: Clinical Educator Track

7. **Primary Department:** Department of Medicine, Division of Hepatology

8. **Secondary/Joint Appointments:** NA

9. **Citizenship:** Indian

10. **Visa Type:** Permanent Resident (USA)

II. Higher Education

11. Institutional:

Bachelor of Medicine and Bachelor of Surgery (M.B.B.S): 07/2001
Andhra Medical College, NTR University of Health Sciences
Andhra Pradesh, India
09/1995 – 06/2001

Master of Public Health (MPH): 12/2007
University of North Texas Health Science Center (UNTHSC)
Fort Worth, TX, USA
01/2002 – 12/2007

12. Non-Institutional:

Mount Sinai School of Medicine: Transplant Hepatology Clinical Fellow
07/2010 – 06/2011

Mount Sinai School of Medicine (Elmhurst Program): Gastroenterology Clinical Fellow
07/2007 – 06/2010

Bronx Lebanon Hospital Center: Chief Resident Internal Medicine
01/2006 – 08/2006

Bronx-Lebanon Hospital Center: Internship and Residency Internal Medicine
08/2003 – 01/2006

13. Certification, licensure:

Transplant Hepatology: American Board of Internal Medicine
Recertification on 2022

Gastroenterology: American Board of Internal Medicine
Recertification on 2020

Internal Medicine: American Board of Internal Medicine
Recertification on 2016

Trained and certified in the use of Fibroscan 502 (Medium Probe), ECHOSENS

Basic Life Support (BLS): Expiration Date: 11/2019

Advanced Cardiac Life Support (ACLS): Expiration Date: 11/2019

Florida Medical License, ME 110085 Expiration 1/30/2019

Ohio Medical License, 35.097912 Inactive

New York Medical License, Temporary 002680 Inactive

III. Experience

14. Academic:

University of Miami Miller School of Medicine: Associate Professor of Clinical
Medicine 06/2017 – Present

University of Miami Miller School of Medicine: Assistant Professor of Clinical Medicine
07/2011 – 05/2017

Miami Transplant Institute: Medical Director for Small Bowel and Multi-Visceral
Transplant: 7/2013 - Present

15. Hospital Appointments:

Jackson Memorial Hospital, Attending Physician 7/2011 – present

University of Miami Hospital & Clinics, Attending Physician 7/2011 – present

University of Miami Hospital Attending Physician 7/2011 – present

MLK Jr. Center/ Bronx-Lebanon Hospital Center, IM Attending 08/2006 – 06/2007

16. Non-Academic: None

17. Military: None

IV. Publications

18. Books and monographs published:

1. Carrion AF, **Bhamidimarri KR**. Chapter 33: Liver Transplantation. Friedman: Handbook of Liver Disease, 4th Edition, 2016.
2. **Bhamidimarri KR**, Martin P. Chapter 43: Acute viral hepatitis. *Clinical infectious disease Second Edition*. David Schlossberg. Cambridge University Press. Chapter 43:287-295, 2015.
3. **Bhamidimarri KR**, Martin P. The HCV viral life cycle and treatment in HIV coinfection and dialysis population. eViral Hepatitis Review. Johns Hopkins Newsletter. Volume 4 Issue 6, 2016.

19. Juried or refereed journal articles or exhibitions:

1. Ayoub WS, Martin P, **Bhamidimarri KR**. Hepatitis B virus infection and Organ Transplantation. *Gastroenterol Hepatol* Jan 2018; Volume 12, Issue 1: 33-40.
2. **Bhamidimarri KR**, Satapathy SK, Martin P. Hepatitis C Virus and Liver Transplantation. *Gastroenterol Hepatol* April 2017; Volume 13, Issue 4:214-220.
3. **Bhamidimarri KR**, Ladino M, Pedraza F, Guerra G, Mattiazzi A, Chen L, Ciancio G, Kupin W, Martin P, Burke G, Roth D. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. *Transpl Int*. 2017 Mar 23. doi: 10.1111/tri.12954. [Epub ahead of print].
4. **Bhamidimarri KR**, Lanza DC, Kashikar ND. Hepatobiliary and Pancreatic: A unique case of HPV related metastatic Schneiderian carcinoma presenting as polycystic liver disease. *J Gastroenterol Hepatol*. 2017 Jan;32(1):10.
5. **Bhamidimarri KR**. Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease. *Ann Transl Med*. 2016 Oct;4(Suppl 1):S13.
6. Berera SR, Gomez A, Dholaria K, Arosemena LR, Ladino-Avellaneda MA, Barisoni L, **Bhamidimarri KR**. A Rare Case of Hepatitis C-Associated Cryoglobulinemic Duodenal Vasculitis. *ACG Case Rep J*. 2016 Sep 28;3(4):e134.
7. Pan CQ, Dai E, **Bhamidimarri KR**, Zeng Z, Yin P. Clinical Features of Chronic Hepatitis B in Treatment-naive Asian Patients With Positive HBeAg and Coexisting Precore and/or Basal Core Promoter Mutations. *J Clin Gastroenterol* 2017 Mar;51(3):261-267.

8. Czul F, **Bhamidimarri KR**. Non-invasive markers to assess liver fibrosis. *Journal of Clinical Gastroenterology*. 2016 Jul;50(6):445-57.
9. Campos I, **Bhamidimarri KR**, Terrault N et al. Treatment of Severe Recurrent Hepatitis C After Liver Transplantation in HIV Infected Patients Using Sofosbuvir-Based Therapy. *Alimentary Pharmacology & Therapeutics*. 2016 Jun;43(12):1319-29.
10. **Bhamidimarri KR**, Martin Paul. Finally safe and effective treatment options for hepatitis c in hemodialysis patients. *Journal of Hepatology*. 2016 Jul;65(1):7-10.
11. **Bhamidimarri KR**, Czul F, Peyton A, Levy C, O'Brien C, Schiff E, Roth D, Martin P. Safety and efficacy of Simeprevir plus half dose Sofosbuvir for Hepatitis C treatment in end stage renal disease. *Journal of Hepatology* 2015.
12. Calmet FH, Yarur AJ, Pukazhendhi G, Ahmad J, **Bhamidimarri KR**. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. *Ann Gastroenterol*. 2015 Jul-Sep;28(3):366-373.
13. Corral JE, Diaz CR, **Bhamidimarri KR**. Metastatic Colorectal Cancer and the Need for More Endoscopic Tools. *J Gastrointest Cancer*. 2015 Sep;46(3):322-4.
14. Gutierrez JA, Carrion AF, Avalos D, O'Brien C, Martin P, **Bhamidimarri KR**, Peyton A. Sofosbuvir and Simeprevir for Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients. *Liver Transpl*. 2015 Jun;21(6):823-30.
15. Patel A, Sclair S, Junaidi O, Copado V, Levy C, Martin P, Rudraraju M, **Bhamidimarri KR**. Response Guided Treatment With Telaprevir or Boceprevir In End Stage Renal Disease Patients With Hepatitis C Genotype 1. *Journal of Gastroenterology and Hepatology Research* 2014 Sep 21 3(9): 1188-1191.
16. **Bhamidimarri KR**, Martin P. Liver transplantation: update of concepts and practice. *Clin Liver Dis*. 2014 Aug;18(3).
17. **Bhamidimarri KR**, Beduschi T, Vianna R. Multivisceral transplantation: where do we stand? *Clin Liver Dis*. 2014 Aug;18(3):661-74.
18. Gumaste VV, **Bhamidimarri KR**, Bansal R, Sidhu L, Baum J, Walfish A. Factors predicting early discharge and mortality in post-percutaneous endoscopic gastrostomy patients. *Ann Gastroenterol*. 2014;27(1):42-47.
19. Levy C, Naik J, Giordano C, Mandalia A, O'Brien C, **Bhamidimarri KR**, Schiff ER, Martin P. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. *Clin Gastroenterol Hepatol*. Aug;12(8):1398-405, 2014.

20. **Bhamidimarri KR**, Schiff E. Drug-induced cholestasis. Clin Liver Dis. Nov;17(4):519-31, 2013.
21. Carrion AF, **Bhamidimarri KR**. Liver transplant for cholestatic liver diseases. Clin Liver Dis. May;17(2):345-59, 2013.
22. Pan CQ, Duan ZP, **Bhamidimarri KR**, Zou HB, Liang XF, Li J, Tong MJ. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. May;10(5):452-9, 2012.
23. **Bhamidimarri KR**, Park J, Dieterich D. Management of Hepatitis B Virus Coinfection: HIV, Hepatitis C Virus, Hepatitis D Virus. Current Hepatitis Reports December, Volume 10, Issue 4, pp 262-268, 2011.
24. **Bhamidimarri KR**, Pan C. Hepatitis B Reactivation During Immunosuppression: From Pathogenesis to Management Strategy. The North American Journal of Medicine and Science (NAJMS), 4 (1): 44-49, 2011.

20. Other works, publications and abstracts:

1. Putting the pieces together: HCV therapy in those with chronic kidney disease. **Bhamidimarri KR**, Martin P. Nov 21, 2016 AGA Perspectives.
2. Modified Hep C regimen may help in severe renal impairment. **Bhamidimarri KR**. Nov 4th, 2015. Hepatology in focus. Gastroenterology and Endoscopy News.
3. The Scary Side Effect of a Daily Lemonade, Fruit Drink or Soda. **Bhamidimarri KR**. June 8, 2015. By Korin Miller, Yahoo Health.
4. Doctors Say ‘Boomers’ Balk at Vital Tests. **Bhamidimarri KR**. August 17, 2013. By Robin Williams Adams, The Ledger.
5. Hepatitis C on the rise among boomers in Broward, Palm. Denial, fear and ignorance keep boomers from getting hep C tests. **Bhamidimarri KR**. July 28, 2013. By Diane C. Lade, Sun Sentinel.

21. Other works accepted for publication:

1. Is Liver biopsy still needed in kidney transplant candidate infected with hepatitis C? Recently won AASLD award.
2. Treatment outcomes of HCV in post liver and kidney transplant recipients.

V. Professional

22. Funded Research Performed as Principal Investigator:

1. VTI210: Randomized, Openlabel, Multicenter, Controlled Study To Assess Safety And Efficacy Of Elad In Subjects With Acute Alcoholic Hepatitis (AAH) Who Have Failed Steroid Therapy Incorporating Vti210e As A Followup Registry.
Total Budget \$ 192, 508.00
2. Synageva LAL-CLO6: Administration Of Sebelipase Alpha In Patients With Lysosomal Acid Lipase Deficiency In At-Risk Patient Populations.
Total Budget \$ 213, 215.00
3. VTI-208; A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects with Alcohol-Induced Liver Decompensation (AILD).
Total Budget \$ 198, 666.00
4. Biotest 988: A Multi Center, Randomized, Prospective, OpenLabel Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin (HCIG) in Orthotopic Liver Transplant Recipients.
Total Budget \$ 115, 250.00
5. AI444216 (PI): A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected with Human Immunodeficiency Virus (HIV).
Total Budget \$ 103, 840.00
6. VTI212: A Randomized, Open label, Multicenter, Controlled Study To Assess Safety And Efficacy Of Elad In Subjects With Fulminant Hepatic Failure (FHF).
Total Budget \$ 183, 015.00.
7. Synageva LALD Screening study: A Study To Identify The Frequency Of Lysosomal Acid Lipase Deficiency In At-Risk Patient Populations.
Total Budget \$ 105, 000.00 (study transferred from Genetics dept).
8. OCR002HE209 Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with an Episode of Hepatic Encephalopathy.
Total Budget \$ 259, 716.00.
9. RNLC2131 (PI): A Randomized Double Blind Placebo Controlled Dose ranging Multi Center Study to assess efficacy and safety of rifaximin solid soluble dispersion tablets (SSD) for the prevention of complications in subjects with early decompensated cirrhosis.
Total Budget \$ 113, 998.00.

Unfunded Research performed as a Principal Investigator:

1. HCV TARGET: Hepatitis C Therapeutic Registry and Research Network A Longitudinal, Observational Study
2. Investigator initiated study: Hepatitis C Treatment in ESRD patients.
3. Investigator initiated study: Hepatitis C Treatment in Post Liver Transplant patients.
4. Study on bacterial infections among hospitalized cirrhotic patients. International club of ascites.
5. HCV Response rates among Asian Americans using Sofosbuvir based regimen (SEESOFA).

Funded Research as a Sub- Investigator:

1. LUM001201 A Phase 2, Randomized, Double blind, Placebo controlled Study To Evaluate Lum001, An Apical Sodium dependent Bile Acid Transporter Inhibitor (ASBTI), In Combination With Ursodeoxycholic Acid (Udca) In Patients With Primary Biliary Cirrhosis.
2. Intcept-747-207: A phase II randomized double blind placebo controlled dose finding clinical trial evaluating the efficacy and safety of obeticholic acid in primary sclerosing cholangitis.
3. Intercept-747-302 (SPI): A phase IIIb randomized placebo controlled multicenter study evaluating the effect of obeticholic acid on clinical outcomes in subjects with primary biliary cirrhosis.
4. LUM001401: A Pilot, Open label Study To Evaluate The Safety, Tolerability And Efficacy Of Lum001, An Apical Sodium dependent Bile Acid Transporter Inhibitor (ASBTI), In Patients With Primary Sclerosing Cholangitis (SPI)
5. Emergency Use of Sofosbuvir (SPI): HCV Post Transplant Compassionate Use For Fibrosing Cholestatic Hepatitis.
6. GSUS3210102 A Phase 2b, Dose Ranging, Randomized, Double Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of GS6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC) (SPI).
7. GSUS2030109A Rollover Protocol to Provide Open Label Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GSUS2030107 Study (SPI)

8. Clinical Study Protocol M13099 A Randomized, Open Label Study to Evaluate the Safety and Efficacy of ABT450/Ritonavir/ABT267(ABT450/r/ABT267) and ABT333 Co-administered with Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) (SPI)
9. GSUS3340154A Phase 2b Randomized, Open Label Study of 200 mg or 400 mg Sofosbuvir RBV for 24 Weeks in Genotype 1 or 3 HCV Infected Subjects with Renal Insufficiency (SPI)
10. Janssen SONET (Simeprevir ObservatioNal Effectiveness across practice settings)/TMC435HPC4003 A Prospective Observational Study to Examine Patient Characteristics, Health Care Management, and Effectiveness Among HCV Patients Treated With Simeprevir at (SPI)
11. MK-5172 (SPI): A phase II randomized open label clinical trial to study the efficacy and safety of combination regimen of MK-5172 and MK-3682 with either MK-8742 or MK-8408 in subjects with chronic hepatitis c GT1, GT2 or GT4 infection.
12. GXUS1740172 Observational, Post-marketing Renal Safety Surveillance Registry in Patients with Chronic Hepatitis B (HBV) Infection with Decompensated Liver Disease Receiving Nucleotide/side Therapy (SPI)
13. AbbVie M14-222 (SPI): An open label multi center study to evaluate long term outcomes with ABT-450/Ritonavir/ABT-267 and ABT-333 with or without ribavirin in adult hepatitis c genotype 1 patients.
14. Clinical Study Protocol M13098 A Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Safety of ABT 450/Ritonavir/ABT267 (ABT450/r/ABT267) and ABT333 Co-administered with Ribavirin (RBV) in Treatment-Experienced Adults (SPI).
15. TMC435HPC2009 – GALAXY (SPI): A phase II open label study in recurrent genotype 1 hepatitis c post orthotopic liver transplant patients to explore the safety and efficacy of sofosbuvir and Simeprevir with or without ribavirin.
16. BMS AI444026070 An Open Label Retreatment Study with PegInterferon Alfa2a, Ribavirin and BMS790052 With or Without BMS650032 for Subjects With Chronic Hepatitis C (SPI).
17. GSUS2480122A Long Term Followup Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection (SPI).
18. GSUS3340153 A Phase 3B Randomized, OpenLabel, MultiCenter TrialAssessing Sofosbuvir Ribavirin for 16 or 24 Weeks and Sofosbuvir Pegylated Interferon

Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection (SPI).

19. GSUS3200110 A Phase 3, Randomized, DoubleBlind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B (SPI).
20. GSUS1740103:A Randomized, DoubleBlind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Hbe Ag Positive Chronic Hepatitis B (SPI).
21. GXUS1740172 Observational, Postmarketing Renal Safety Surveillance Registry in Patients with Chronic Hepatitis B (HBV) Infection with Decompensated Liver Disease Receiving Nucleotide/side Therapy (SPI).
22. Elucidation of the Role of Statins in Prevention of Hepatocellular Carcinoma (SPI).
23. sPIF: A phase I randomized double blind placebo controlled Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF), a Novel Immune-Modulating Biologic, in Females with Autoimmune Hepatitis (SPI).

23. Editorial responsibilities:

2016 – Present	Editorial board member, Liver Transplantation.
2016 – Present	Peer-Reviewer, Medicine.
2015 – Present	Peer-Reviewer, Biomed Central (BMC) Gastroenterology.
2014 - Present	Co-Editor, Clinical Liver Disease. Care of the cirrhotic patient.
2013 – Present:	Peer-Reviewer, ACG Case Reports Journal.
2013 – 2016:	Editorial board member, World Journal of Hepatology.
2013 – 2014:	Co-Editor, Clinics in Liver Disease Volume 18, Issue 3. Liver Transplantation: Update in concepts and practice.
2013	Cambridge University author.

24. Professional and Honorary Organizations:

2013 – Present: Florida Gastroenterologic Society (FGS).
2012 – Present: American Society of Transplantation (AST)
- Liver and Intestinal Community of Practice (LICOP) member
2012 – Present: European Association for the Study of the Liver (EASL)
2011 – Present: Clinical competency committee University of Miami
- Transplant Hepatology fellowship
2007 - Present: American Association for the Study of Liver Diseases (AASLD)
- Publications Committee member.
2007- Present: American Gastroenterological Association (AGA)

- Academy of Educators member
- Tele-mentor, World Gastroenterology Organization: WGO-AGA-TSG training center, Ankara, Turkey.
- Faculty Development for Clinical Educators. How to write test questions for ABIM GI boards.

2007 – Present: American College of Gastroenterology (ACG)

- Peer Reviewer ACG Case Reports.

2007 – Present: American Society for Gastrointestinal Endoscopy (ASGE)

2007 – Present: New York Society for Gastrointestinal Endoscopy (NYSGE)

1995 – Present: Andhra Medical College Old Students Association (AMCOSA)

25. Honors and Awards:

2009: Dr. David Falkenstein Award: Best Presentation on fellow’s night, New York Society for Gastrointestinal Endoscopy (NYSGE)

2000: Sajja Chandra Mouli Gold Medal in clinical neurology

2000: Vemuri Sivaji Rao Gold Medal in Medicine – first in the University.

26. Post-Doctoral Fellowships: NA

27. Other Professional Activities:

Scientific Advisory Board Member:

December 2017:	Eisai Pharmaceuticals
December 2017:	Merck Sciences, HCV Therapeutics.
June 2017 :	Gilead Sciences, HBV therapeutics.
May 2017:	Merck Sciences, HCV Therapeutics
March 2017:	Alexion Pharma, LAL deficiency
February 2017:	Intercept, Ocaliva
December 2016:	Gilead Sciences, HCV Therapeutics.
November 2016:	AbbVie, HCV Therapeutics.
June 2016:	AbbVie, HCV Therapeutics.
May 2016:	Gilead Sciences, HBV Therapeutics.
May 2016:	Gilead Sciences, HCV Therapeutics.
April 2016:	Salix/ Valeant, Hepatic encephalopathy
December 2015:	Gilead Sciences, HBV Therapeutics.
September 2015:	Bristol-Myers Squibb, HCV Therapeutics.
July 2015:	Synageva (LALD clinical educator), LAL deficiency.
June 2015:	Gilead Sciences, HCV Therapeutics.
May 2015:	Janssen Therapeutics, HCV Therapeutics.
September 2014:	AbbVie, HCV Therapeutics.
May 2014:	Janssen, HCV Therapeutics.
January 2014:	Genentech/ Roche, HCV Therapeutics.
September 2013:	Gilead Sciences, HBV Therapeutics.

Major Invited Speeches:

International Speeches:

1. March 14th – 18th, 2018: Asia Pacific Association for Study of Liver diseases (APASL). New Delhi, India.
2. Dec 18th, 2016: 57th Annual conference of Indian Society of Gastroenterology, ISGCON. Hotel Pullman, Aerocity, New Delhi. Challenges in diagnosing Autoimmune hepatitis.
3. Sep 3rd, 2015: Sardar Patel College, Hyderabad, India: Raising awareness for hepatitis in India: Hepatitis A to Z.

National Speeches:

1. Dec 12th, 2017: National Association for Continuing Education (NACE). SCALE HBV. Costa Mesa, LA.
2. Oct 28th, 2017: National Association for Continuing Education (NACE). Sheraton Miami Airport and Executive Meeting Center. SCALE HBV. Miami, FL.
3. Oct 21st, 2017: National Association for Continuing Education (NACE). Dallas/ Addison Marriott Quorum by the Galleria. SCALE HBV. Dallas, TX.
4. Oct 7th, 2017: National Association for Continuing Education (NACE). Seattle Airport Marriott. SCALE HBV. Seattle, WA.
5. Sep 21st, 2017: National AIDS Treatment and Advocacy Project (NATAP), Atlanta, GA. Hepatitis C cure updates: 2017 New Treatments and Breakthroughs.
6. Sep 16th, 2017: National Association for Continuing Education (NACE), Renaissance Orlando Airport. SCALE HBV. Orlando, FL.
7. May 19th, 2017: National AIDS Treatment and Advocacy Project (NATAP). Hepatitis C cure updates: 2017 New Treatments and Breakthroughs. Miami-Dade College, Miami, FL.
8. May 7th, 2017: Co-chair AASLD topic forum with Roberto J Firpi. Cirrhosis Complications. DDW 2017, McCormick place, Chicago, IL.
9. March 11th, 2017: XXII Hepatobiliary Disease in Clinical Practice. Controversies in Liver Transplantation. Intercontinental Hotel, Miami, FL.
10. Dec 8th, 2016: Intercept Preceptorship. PBC: Understanding the disease. Miami, FL.
11. Nov 7th, 2016: American Liver Foundation/ Ask the Experts forum. Hepatitis and rare liver diseases. Miami, FL.

12. Nov 4th, 2016: Synergy: Panel discussion on current treatment of hepatocellular carcinoma. Eden-Roc Hotel, Miami, FL.
13. Oct 22nd, 2016: National Association for Continuing Education (NACE), Phoenix, AZ. SCALE HBV.
14. Oct 15th, 2016: National Association for Continuing Education (NACE), Dallas, TX. SCALE HBV.
15. Sep 23rd, 2016: National AIDS Treatment and Advocacy Project (NATAP), Atlanta, GA. Hepatitis C cure has arrived.
16. Sep 15th, 2016: National Association for Continuing Education (NACE), Orlando, FL. SCALE HBV.
17. June 14th, 2016: American Transplant Congress, Hynes Convention Center, Boston, MA. Work up of abnormal LFT's in a transplant candidate.
18. May 20th 2016: National AIDS Treatment and Advocacy Project (NATAP), Miami Dade College Medical Campus. HCV treatment in the new era of DAA's.
19. March 19th, 2016: American College of Gastroenterology/ Florida Gastroenterological Society Annual Spring Course, Hyatt Regency Coconut point, Bonita Springs, FL. Update in HCV Treatment.
20. Oct 17th, 2015: National Association for Continuing Education (NACE), Marriott San Diego, La Jolla, CA. Emerging Challenges in Primary Care. Nonalcoholic Steatohepatitis: Identification and Evolving Treatment Strategies.
21. Oct 17th, 2015: National Association for Continuing Education (NACE), Marriott San Diego, La Jolla, CA. Emerging Challenges in Primary Care. Chronic Hepatitis C: Update on Screening, Diagnosis, Management, and Promising New Treatments.
22. Oct 24th, 2015: National Association for Continuing Education (NACE), Loews Vanderbilt Hotel, Nashville, TN. Emerging Challenges in Primary Care. Nonalcoholic Steatohepatitis: Identification and Evolving Treatment Strategies.
23. Oct 24th, 2015: National Association for Continuing Education (NACE), Loews Vanderbilt Hotel, Nashville, TN. Emerging Challenges in Primary Care. Chronic Hepatitis C: Update on Screening, Diagnosis, Management, and Promising New Treatments.
24. Oct 24th, 2015: Miami Transplant International Symposium (MTISympo), Fountainebleu Miami Beach Hotel, Miami, FL. Present & Future of Immunosuppression Therapy in Liver Transplantation.
25. Nov 13th, 2015: Med-IQ: Strategies for success as a patient-centered medical home, Hyatt Regency, Pier 66, FLL, FL. Hepatitis C (developed by Mark Sulkowski).

26. Sep 18th, 2015: National AIDS Treatment and Advocacy Project (NATAP), Atlanta, GA. Hepatitis C cure has arrived.
27. May 17th, 2015: Digestive Disease Week, DDW 2015, AASLD Clinical Symposium. Walter E Washington Convention Center, Washington D.C. Hepatitis C Treatment Recommendations for 2015: Management of HCV in CKD.
28. May 5th, 2014: Digestive Disease Week, DDW 2014, AASLD Clinical Symposium. McCormick Place, Chicago, Illinois. Early Diagnosis and Treatment of HCC, Case Discussion: Small Non Diagnostic Imaging in Probably Future OLT Candidate Biopsy or Wait for Growth.
29. April 6th, 2013: National Kidney Foundation (NKF) 2013 Spring Clinical Meetings (SCM13). Walt Disney World Swan and Dolphin in Orlando, Florida. Novel Therapies in Viral Infections and Kidney Disease.

Regional/ State Speeches:

- a. March 12th, 2017: 22nd Biannual Update of Hepatobiliary Diseases. Intercontinental Hotel, Miami, Florida. Controversies in Liver Transplant.
- b. March 13th, 2015: 21st Biannual Update of Hepatobiliary Diseases. Intercontinental Hotel, Miami, Florida. Treating HCV Special Populations.
- c. Feb 6th-7th, 2015: Guerbet Miami HCC and NETs Intensive Conference. Westin Colonnade Hotel, Miami, Florida. Hepatocellular Carcinoma: Past, Present and Future.
- d. Dec 3rd, 2014: Grand Rounds, St. Mary's Medical Center, Evansville, Indiana. Innovations in Treating HCV.
- e. Nov 1st, 2014: Hepatitis Symposium, Hyatt Hotel, Miami, Florida. The HCV pipeline and Treatment Recommendations.
- f. Sep 6th, 2014: New Directions in Primary Care Management, Hyatt Hotel, Miami, Florida. Innovations in Treating Hepatitis C.
- g. Aug 28th, 2014: BMS-UM Preceptorship, University of Miami. Hepatitis C Pre and Post-Transplant Experience.
- h. Aug 12th, 2014: Grand Rounds, Flagstaff Medical Center, Arizona. Innovations in treating Hepatitis C.
- i. Aug 6th, 2014: Grand Rounds, Henderson Medical Center, Kentucky. Innovations in treating Hepatitis C.
- j. Jun 27th, 2014: Nurses in-service, Broward Department of Health. Understanding the community impact of hepatitis.

- k. Jun 13th, 2014: NATAP (National AIDS Treatment Advocacy Project), Miami Dade College Medical Campus. Hepatitis C: Management, Treatment Strategies And New Drugs For A Cure.
- l. May 28th, 2014: Grand Rounds, University of Miami. Viral Hepatitis: A to Z.
- m. November 21st, 2013: Grand Rounds in Bronx-Lebanon Hospital Center, Bronx, NY. Hepatitis B Update.
- n. September 22nd, 2013: Florida Gastroenterologic Society Annual Meeting 2013. Hyatt Regency Grand Cypress Resort, Orlando, Florida. The epidemic of Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment.
- o. April 12th 2013: 3rd Annual Transgender Medical Symposium, Florida/ Caribbean AIDS Education and Training Center. Embassy Suites Hotel, Fort Lauderdale, Florida: An update on viral hepatitis.
- p. June 13th, 2012: Bayer Hepatocellular Carcinoma Multidisciplinary Symposium, University of Miami. Inoperable Hepatocellular Carcinoma.

Poster Presentations:

1. Oral Presentation, Kidney Week, ASN 2017, New Orleans, LA: Comparison of Outcomes after DAA therapy among HCV-infected kidney transplant recipients who received grafts from either HCV-positive or negative donors. Sedki M, Cortesi C, O'Brien C, Levy C, Martin P, Roth D, **Bhamidimarri KR**. JASN abstract SUPP 2017. FR-OR087.
2. Oral Presentation, AASLD 2017, Washington DC: Comparison of Outcomes after DAA therapy among HCV-infected kidney transplant recipients who received grafts from either HCV-positive or negative donors. Sedki M, Cortesi C, O'Brien C, Levy C, Martin P, Roth D, **Bhamidimarri KR**. Hepatology, Vol. 66, Number 1 (SUPP), Page 111A.
3. Poster Presentation, AASLD 2017, Washington DC: Geographic Differences for Patients Enrolled in STOP-HE: A Randomized, Phase 2 Study of OCR-002 for Hepatic Encephalopathy. Thabut D, Stadlbauer V, **Bhamidimarri KR**, Pothoff A, Bukofzer S. Hepatology, Vol. 66, Number 1 (SUPP), Page 274A.
4. Poster Presentation, AASLD 2017, Washington DC: STOP-HE: A Randomized, Double-blind, Placebo-controlled Study of OCR-002 in Patients with Hepatic Encephalopathy. Rahimi RS, Safadi R, Thabut D, Bajaj JS, **Bhamidimarri KR**, Pysopoulos NT, Pothoff A, Bukofzer S. Hepatology, Vol. 66, Number 1 (SUPP), Page 276A.
5. Poster Presentation, AASLD 2017, Washington DC: Is liver biopsy still necessary in evaluating HCV infected kidney transplant candidate? Cottone C, Calmet FH, Levy C,

O'Brien C, Martin P, **Bhamidimarri KR**. Hepatology, Vol. 66, Number 1 (SUPP), Page 334A.

6. Poster Presentation, AASLD 2017, Washington DC: Direct Acting Antiviral Therapy is Associated with Shorter Time to HCC Recurrence but not Increased Risk of Recurrence. Singal AG, Hoteit MA, John B, Kulik LM, Eswaran SL, Jou JH, Tran TH, Wong RJ, **Bhamidimarri KR**, Rich NE, Mitrani R, Konjeti VR, Ghoulam E, Odewole M, Parikh ND. Hepatology, Vol. 66, Number 1 (SUPP), Page 729A.
7. Poster Presentation, International Liver Cancer Association (ILCA), Seoul, Korea 2017: Direct Acting Antiviral Therapy is Associated with Shorter Time to Hcc Recurrence but not Increased Risk of Recurrence. Singal AG, Hoteit MA, John B, Kulik LM, Eswaran SL, Jou JH, Tran TH, Wong RJ, **Bhamidimarri KR**, Rich NE, Mitrani R, Konjeti VR, Ghoulam E, Odewole M, Parikh ND.
8. Poster Presentation, DDW 2017, Chicago, IL: Efficacy and Safety of Sofosbuvir-Based Regimens in a National Cohort of Asian-American Patients with Chronic Hepatitis C. Calvin Q. Pan, Benjamin Tiongson, Ke-Qin Hu, Myron J. Tong, Danny Chu, James Park, **Bhamidimarri KR**, Xiaoli Ma, Tai-Ping Lee, Pei ying Xiao, Dan Wang. Gastroenterology, Vol. 150, Issue 4, S1098.
9. Poster Presentation DDW 2017, Chicago, IL: Natural History of Hepatic Sarcoidosis in an Ethnically Diverse Population. Nogueira NF, Santiago P, Diaz LI, **Bhamidimarri KR**, Cynthia Levy. Gastroenterology, Vol. 152, Issue 5, S1186.
10. Poster Presentation DDW 2017, Chicago, IL: Long Term Effects on Immunosuppression and Renal Function After Direct Acting Antiviral Therapy for Recurrent Hepatitis C in Liver Transplant. Recipients. Sedki M, Cortesi C, Sheth R, Martin P, **Bhamidimari KR**. Gastroenterology, Vol. 152, Issue 5, S1098.
11. Poster Presentation, EASL ILC 2017, Amsterdam: Summary of the FDA report: twenty four hepatitis B reactivation cases during hepatitis C direct acting antiviral therapy. **Bhamidimarri KR**, D. Widjaja , S. Satapathy , C. O'Brien , P. Martin.
12. Poster Presentation, AASLD 2016, Boston, MA: Diagnostic Value of Transient Elastography for Detection of Hepatic Fibrosis in Liver Transplant Recipients: A Systematic Review and Meta-Analysis. Faisal Kamal, Muhammad Ali Khan, Ollie D. Jones, **Bhamidimarri KR**, Satheesh Nair, Sanjaya K. Satapathy.
13. Poster Presentation, AASLD 2016, Boston, MA: RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/ Ritonavir and Dasabuvir with or without Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection with Severe Renal Impairment or End-Stage Renal Disease. John M. Vierling, Eric Lawitz, K. Rajender Reddy, Eric Cohen, Nyingi Kemmer, Giuseppe Morelli, Philippe J. Zamor, Michael Bennett, David E. Bernstein, Kris V. Kowdley, Parvez S. Mantry, Paul J. Pockros,

David L. Wyles, Sonal Kumar, **Bhamidimarri KR**, Daniel E. Cohen, Tami Pilot-Matias, Wangang Xie, Thomas Podsadecki, Tarek I. Hassanein.

14. ***Presidential Poster Award, AASLD 2016, Boston, MA: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF), a Novel Immune-Modulating Biologic, in Autoimmune Hepatitis. Christopher O'Brien, Eytan R. Barnea, Paul Martin, Cynthia Levy, **Bhamidimarri KR**, Eden Sharabi, Eugene R. Schiff.
15. Oral Presentation, DDW 2016, San Diego, CA: Impact of Gender On Clinical Presentation, Response To Treatment, And Long-Term Outcomes In An Ethnically Diverse Population of Patients With Autoimmune Hepatitis. Donet J, Perlini E, Gilinsky D, Huang M, **Bhamidimarri KR**, Levy C.
16. Poster Presentation, DDW 2016, San Diego, CA: Environmental risk factors and socioeconomic disparity in Hispanic versus non-Hispanic patients with PBC. Rabiee A, Polanco NAP, De La Vara AF, **Bhamidimarri KR**, Levy C.
17. Poster Presentation, EASL ILC 2016, Barcelona, Spain: Renal function decline is frequent in patients undergoing hepatitis c treatment post kidney transplant. **Bhamidimarri KR**, Martin P, Levy C, Roth D. Journal of Hepatology 2016.
18. Poster Presentation, Kidney Week 2015, San Diego, CA: Can Acute-On-Chronic Liver Failure Classification Predict Post-Liver Transplant and Liver Kidney Transplant Outcomes? Guerra G, Tryphonopoulos P, **Bhamidimarri KR**, Thomas I, Vianna R. J Am Soc Nephrol 26: 2015, page 876A.
19. Poster Presentation, Kidney Week 2015, San Diego, CA: Direct Acting Antiviral Agents for HCV-Infected Patients Transplanted with a Kidney from a HCV Positive Donor. Roth D, Goldstein M, Kupin WL, Guerra G, Chen LJ, Mattiazzi AD, Ciancio G, Martin P, Burke GW, **Bhamidimarri KR**. Am Soc Nephrol 26: 2015, page 878A.
20. Oral Poster Presentation, AASLD 2015, San Francisco, CA: Prevention of Recurrent Hepatitis C in Liver Transplant (LT) Recipients with Civacir®: Preliminary Results on Safety and Efficacy, Including Patients with Renal/Liver Dysfunction. Terrault N, **Bhamidimarri KR** et al. HEPATOLOGY (2015).
21. ***Presidential Poster Award, AASLD 2015, San Francisco, CA: Hepatitis C Cure Could Avoid Liver Transplant In Some Cirrhotic Patients On Dialysis Listed for Simultaneous Liver Kidney Transplantation. Czul F, Roth D, Vianna R, Levy C, Martin P, **Bhamidimarri KR**. HEPATOLOGY (2015).
22. Poster Presentation, AASLD 2015, San Francisco, CA: Clinical Features of Chronic Hepatitis B (CHB) in Treatment-Naive Asian Patients with Positive HBeAg and

- Coexisting Pre-core and/or Basal Core Promoter (PC/BCP) Mutations. Pan CQ, Dai E, **Bhamidimarri KR**, Zeng Z, Yin P. HEPATOLOGY (2015).
23. Poster Presentation, AASLD 2015, San Francisco, CA: Safety, Efficacy and Tolerability in the treatment of patients with Chronic Hepatitis C and Severe Renal Impairment. Czul F, Peyton A, O'Brien C, Jeffers L, Martin P, **Bhamidimarri KR**. HEPATOLOGY (2015).
 24. Poster Presentation, AASLD 2015, San Francisco, CA: Preliminary Experience Of Direct Acting Antiviral Therapy In Hepatitis C Infected Kidney Transplant Recipients, Who Received Grafts From Hepatitis C Positive Or Negative Donors. **Bhamidimarri KR**, Roth D, Guerra G, Levy C, Martin P. HEPATOLOGY (2015).
 25. Poster Presentation, AASLD 2015, San Francisco, CA: Efficacy of Sofosbuvir and Simeprevir (COSMOS Regimen) in Hepatitis C Genotype 1 in Decompensated Cirrhosis: A tertiary-center Experience. Eduardo R, Levy C, Martin P, **Bhamidimarri KR**. HEPATOLOGY (2015).
 26. ePoster Presentation, EASL ILC 2015, Vienna, Austria: Prevention of Hepatitis C Virus (HCV) Recurrence with Peri-Transplant Hepatitis C Immune Globulin Combined with Pre-Transplant (Pre-LT) Antiviral Therapy (AVT). Terrault N, **Bhamidimarri KR** et al. J of Hepatology (2015).
 27. ePoster Presentation, EASL ILC 2015, Vienna, Austria: First Ribavirin-Free Sofosbuvir And Simeprevir Treatment Of Hepatitis C Genotype 1 Patients With Severe Renal Impairment (Gfr <30ml/Min Or Dialysis). Czul F, Peyton A, Jeffers L, Schiff E, Hernandez M, Levy C, Martin P, **Bhamidimarri KR**. J of Hepatology (2015).
 28. ePoster Presentation, EASL ILC 2015, Vienna, Austria: Safety And Efficacy Of Sofosbuvir And Simeprevir Treatment In Hepatitis C Genotype 1 Liver Transplant Recipients With Advanced Fibrosis/ Recurrent Cirrhosis. **Bhamidimarri KR**. J of Hepatology (2015).
 29. ***Poster of Distinction, DDW 2015, Washington, DC: Insurance Approval Patterns for IFN-free Regimens in HCV: Impact of National Guidelines. Avalos DJ, Schweitzer M, Peyton A, **Bhamidimarri KR**, Gutierrez JA. Gastrointestinal Endoscopy (April 2015).
 30. Poster Presentation, DDW 2015, Washington, DC: An Indirect Comparison of Interferon-free Treatments among Genotype 1 Hepatitis C naïve and Experienced Patients: A Network Meta-analysis. Rodriguez EA, Valluri SKA, Pino JE, Larsen MF, **Bhamidimarri KR**. Gastrointestinal Endoscopy (April 2015).
 31. Poster Presentation, DDW 2015, Washington, DC: Characterization of serious adverse events in Hepatitis C genotype 1 decompensated cirrhotic patients who underwent

- Sofosbuvir and Simeprevir therapy (COSMOS regimen). Czul F, Peyton A, Martin P, **Bhamidimarri KR**. *Gastrointestinal Endoscopy* (April 2015).
32. Oral Presentation, DDW 2015, Washington, DC: Elevated serum alkaline phosphatase at follow-up is associated with worse outcomes in Primary Sclerosing Cholangitis. Levy C, Perlini E, Pino JE, **Bhamidimarri KR**, Peyton A, Hernandez MD, O'Brien C, Schiff ER, Martin P. *Gastrointestinal Endoscopy* (April 2015).
 33. Poster Presentation, Research Day, University of Miami: PHASE II TRIAL OF SOM230(PASIREOTIDE LAR) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC). L.Feun, N. Savaraj, K. Blackburn, M. Wangpaichitr, D Kwon, C. O'Brien, C. Levy, **K.R. Bhamidimarri**, A. Peyton, G. Selvaggi, P. Martin
 34. Poster Presentation, AASLD 2014, Boston, MA: Urgent Treatment With Sofosbuvir Based Regimen For Hepatitis C Genotype 1 Patients With Severe Renal Insufficiency (GFR <30ml/min). **Bhamidimarri KR**, Gutierrez JA, Grigorian A, Peyton AL, Levy C, O'Brien C, Martin P. *HEPATOLOGY*, Volume 60, Issue S1, October 2014.
 35. Poster Presentation, AASLD 2014, Boston, MA: Safety and Efficacy of Hepatitis C Therapy with Sofosbuvir and Simeprevir after Liver Transplantation. Gutierrez J, **Bhamidimarri KR** et al. *HEPATOLOGY*, Volume 60, Issue S1, October 2014.
 36. Poster Presentation, AASLD 2014, Boston, MA: Prevention of Hepatitis C Virus (HCV) Recurrence with Peri-Transplant Hepatitis C Immune Globulin Combined with Pre-Transplant (Pre-LT) Antiviral Therapy (AVT). Terrault N, **Bhamidimarri KR** et al. *HEPATOLOGY*, Volume 60, Issue S1, October 2014.
 37. Poster Presentation, ACG 2014, Philadelphia, PA: Serum Vitamin B12 Level Could Be A Novel Diagnostic Marker To Predict Cirrhosis In Patients With Chronic Liver Disease. Czul F, **Bhamidimarri KR**. *American Journal of Gastroenterology* (October 2014).
 38. Poster Presentation, ACG 2014, Philadelphia, PA: A Rare Case of Hepatitis C-Associated Cryoglobulinemic Duodenal Vasculitis. Berera S, Alexandra Gomez A, Arosemena LR, Dholaria K, **Bhamidimarri KR**. *American Journal of Gastroenterology* (October 2014).
 39. Poster Presentation, ACG 2014, Philadelphia, PA: Successful Renal Transplant in Epstein Syndrome: a Rare Cause of Thrombocytopenia Diagnosed During Pre-Transplant Evaluation. Berera S, Calmet FH, **Bhamidimarri KR**. *American Journal of Gastroenterology* (October 2014).
 40. Poster Presentation, AASLD 2013, Washington, DC: Differences in Epidemiology and Clinical Presentation of PSC Across Races and Ethnicities. Pastorini C, Pino JE, Aye L,

Dejman A, **Bhamidimarri KR**, Martin P, Levy C. HEPATOLOGY, Volume 58, Issue S1, October 2013.

41. Poster Presentation, AASLD 2013, Washington, DC: Preliminary Experience Of Hepatitis C Genotype 1 Treatment Response With Either Telaprevir Or Boceprevir Based Regimen In Patients With End Stage Renal Disease On Dialysis. **Bhamidimarri KR**, Sclair S, Franco M, Patel A, Junaidi O, Copado V, Levy C, Martin P, Rudraraju M. HEPATOLOGY, Volume 58, Issue S1, October 2013.
42. Poster Presentation, AASLD 2013, Washington, DC: Hepatitis C Genotype 1 Treatment Response And Outcomes Utilizing Combination Therapy With Telaprevir, Pegylated Interferon Alfa 2a And Ribavirin In Liver Transplant Recipients With Recurrent Cirrhosis. **Bhamidimarri KR**, Peyton A, Aye L, Patel A, Junaidi O, Copado V, Levy C, Martin P, Rudraraju M. HEPATOLOGY, Volume 58, Issue S1, October 2013.
43. Poster Presentation, EASL ILC 2013, Amsterdam, Netherlands: Telaprevir Or Boceprevir Therapy In Chronic Hepatitis C Patients With End Stage Renal Disease On Hemodialysis Is Safe, Tolerable And Feasible. Sclair S, Patel A, Junaidi O, Copado V, Martin P, Rudraraju M, **Bhamidimarri KR**. HEPATOLOGY (April 2013).
44. Poster Presentation, ACG 2012, Las Vegas, NV: Anemia Is not Predictive of Sustained Virological Response, Early Virological Response or Rapid Virological Response in Post-Transplant Patients with Hepatitis C. Giordano CM, Biagini T, **Bhamidimarri KR**. American Journal of Gastroenterology (October 2012).
45. Poster Presentation, ACG 2012, Las Vegas, NV: Case of Seronegative Autoimmune Pancreatitis and Autoimmune Hepatitis with Severe Extrahepatic Biliary Stricturing and Excellent Response to Steroids. Regalado N, **Bhamidimarri KR**. American Journal of Gastroenterology (October 2012).
46. Poster Presentation, ACG 2012, Las Vegas, NV: A Challenging Case of Duodenal Self-expandable Metal Stent Placement in a Patient with Situs Inversus Totalis to Palliate Gastric Outlet Obstruction Caused by Pancreatic Adenocarcinoma. Perlini E, Biagini T, Larsen M, Bhamidimarri KR. American Journal of Gastroenterology (October 2012).
47. Poster Presentation, ACG 2012, Las Vegas, NV: A Rare Case of Refractory Bone Marrow Failure with Acute Liver Failure in an Otherwise Healthy Adult. Woo G, **Bhamidimarri KR**. American Journal of Gastroenterology (October 2012).
48. Poster Presentation, ACG 2012, Las Vegas, NV: The Development of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) in a Patient with Hepatitis C Virus Cirrhosis on Telaprevir. Agresti N, Grajeda JC, **Bhamidimarri KR**, Martin P, O'Brien C, Schiff E. American Journal of Gastroenterology (October 2012).
49. Poster Presentation, ACG 2012, Las Vegas, NV: First Case Report of Post Liver Transplant Adrenal Metastasis of Hepatocellular Carcinoma That's Well Within Milan

Criteria. Perlini E, Biagini T, **Bhamidimarri KR**. American Journal of Gastroenterology (October 2012).

50. Poster Presentation, ACG 2012, Las Vegas, NV: A Probable Case of Hereditary Hemorrhagic Telangiectasia with Recurrent Massive Gastrointestinal Bleeding Requiring Hemicolectomy Despite Medical Management. Carlile R, Kerman D, **Bhamidimarri KR**. American Journal of Gastroenterology (October 2012).
51. Poster Presentation, AASLD 2011, San Francisco, CA: **Bhamidimarri KR**, Ahmad J. Prevalence Of Endoscopic And Histologic Features Of Mycophenolate Mofetil Related Colonic Mucosal Changes In Patients After Solid Organ Transplant. HEPATOLOGY (November 2011).
52. Poster Presentation, ACG 2011, Washington, DC: Ranjan P, **Bhamidimarri KR**, Ahmad J. Balloon Expandable Covered Coronary Stent Used to Manage a Post Liver Transplant Case with Recurrent Hemobilia and Recurrent Cholangitis Due to Hepatic Arterio biliary Fistula. American Journal of Gastroenterology (October 2011).
53. Poster Presentation, ACG 2011, Washington, DC: Vijayvargiya P, **Bhamidimarri KR**, Grewal P. Delayed Esophageal Perforation after Treatment for Recurrent Esophageal Variceal Bleeding. American Journal of Gastroenterology (October 2011).
54. Poster Presentation, ACG 2011, Washington, DC: Lin YT, **Bhamidimarri KR**, Xie J. Study of Demographic and Pathologic Factors Associated with Early Onset Gastric Cancer. American Journal of Gastroenterology (October 2011).
55. Poster Presentation, ACG 2010, San Antonio, TX: **Bhamidimarri KR**, Leytin A, Xie JL, Aron J, Gumaste VV. Pyloric Gland Adenoma In Hispanics. American Journal of Gastroenterology (October 2010) Volume 105, Page S174.
56. Poster Presentation, ACG 2010, San Antonio, TX: **Bhamidimarri KR**, Sidhu L, Xie JL, Pulakhandam U, Gumaste VV. Gastrointestinal Manifestations in Cutaneous astocytosis Evolving into Systemic Mastocytosis. American Journal of Gastroenterology (October 2010) Volume 105, Page 348.
57. Poster Presentation, ACG 2010, San Antonio, TX: **Bhamidimarri KR**, Chauhan MIS, Baum J, Walfish A. Colonoscopic Diagnosis of Polypoid Endometriosis in the Sigmoid Colon. American Journal of Gastroenterology (October 2010) Volume 105, Page 314.
58. Poster Presentation, ACG 2010, San Antonio, TX: **Bhamidimarri KR**, Chauhan MIS, Leytin A, Aron J, Xie JL. Moderately Differentiated Adenocarcinoma Co-Existing in a Large Hyperplastic Gastric Polyp. American Journal of Gastroenterology (October 2010) Volume 105, Page S175.
59. Poster Presentation, ACG 2010, San Antonio, TX: **Bhamidimarri KR**, Chauhan MIS, Kim U, Leytin A, Baum J, Gumaste VV. Fifth Case Report of Extrahepatic

Cholangiocarcinoma Presenting with Cutaneous Nodules as the First Sign of Distant Metastases. American Journal of Gastroenterology (October 2010) Volume 105, Page S195.

60. Poster Presentation, ACG 2010, San Antonio, TX: **Bhamidimarri KR**, Ali S, Gumaste VV. Asymptomatic Case of Agenesis of Dorsal Pancreas in an Elderly Man. First Sign of Distant Metastases. American Journal of Gastroenterology (October 2010) Volume 105, Page S197.
61. Poster Presentation, DDW 2010, New Orleans, LA: **Bhamidimarri KR**, Bansal R, Gumaste VV. Analysis of Factors That Influence The Length of Hospitalization After Percutaneous Endoscopic Gastrostomy Tube Placement. Gastrointestinal Endoscopy (April 2010), Volume 71, Issue 5, Pages AB355.
62. Poster Presentation, DDW 2009, Chicago, IL: **Bhamidimarri KR**, Gumaste VV, Walfish A. Comparison Of Outcomes Of Endoscopic Management Of Gastrointestinal Foreign Bodies Among Prison Inmates To That Of The General Population - A New York City Hospital Experience. Gastrointestinal Endoscopy (April 2009), Volume 69, Issue 5, Pages AB321-AB321.
63. Poster Presentation, ACG 2008, Orlando, FL: **Bhamidimarri KR**, Pan CQ. Treatment Outcomes of Entecavir, Adefovir and Telbivudine in HBeAg positive Chronic Hepatitis B Patients Who Failed Prior Pegylated Interferon Therapy. The American Journal of Gastroenterology (September 2008) Volume 103, Page S143.
64. **Bhamidimarri KR**. (2007, November). The Dose Dependent Effect of Alcohol Consumption. Poster presented at: University of North Texas Health Science Center; Fort Worth, TX.
65. Bhalodkar NC., Blum S., Lone B., Prasad Y., **Bhamidimarri KR**., Heller E., (2004, December). Prevalence of Abnormal Myocardial Perfusion SPECT Imaging Among Asymptomatic Diabetic and Non-Diabetic Blacks and Hispanics in an Inner-City Hospital. Poster presented at: Bronx-Lebanon Hospital Center; Bronx, NY.
66. Lee SK., Manning S., **Bhamidimarri KR**., Sanghvi C. (2003, November). Annual communicable disease report, 2001. Poster presented at: Tarrant County Public Health; Fort Worth, TX.

VI. Teaching

28. **Teaching Awards Received:** None.

29. **Teaching Specialization (courses taught):**

1. FEB, 2015: Core-Curriculum lectures to GI Fellows:
 - a) Structure and Function of Liver.

2. AUG, 2014: Core-Curriculum lectures to MD; MPH Students:
 - a) Structure and Function of Liver.
 - b) Hereditary and Metabolic Liver Disease.
3. AUG, 2014: Core-curriculum lectures to GI Fellows:
 - a) Interpretation of Abnormal LFT's
4. APR, 2014: Core-curriculum lectures to GI Fellows:
 - a) Hereditary and Metabolic Liver Disease.
5. NOV, 2013: Core-Curriculum Lectures to MD Students:
 - a) Hereditary and Metabolic Liver Disease.
6. AUG 2013: Core-Curriculum Lectures to MD; MPH Students:
 - a) Structure and Function of Liver.
 - b) Hereditary and Metabolic Liver Disease.
7. 2013: Board Review Course to Gastroenterology Fellows:
 - a) Cirrhosis and Liver Transplantation.
8. 2012: Core-Curriculum Lectures to Hepatology Fellows:
 - a) Hepatitis B Update.
9. AUG 2012: Core-Curriculum Lectures to MD; MPH Students:
 - a) Structure and Function of Liver.
 - b) Hereditary and Metabolic Liver Disease.
 - c) Liver Tumors.
10. NOV 2012: Core-Curriculum Lectures to Medical Students:
 - a) Hereditary and Metabolic Liver Disease.
 - b) Liver Tumors.
11. NOV 2011: Core-Curriculum Lectures to Medical Students:
 - a) Structure and Function of Liver.
 - b) Hereditary and Metabolic Liver Disease.
 - c) Liver Tumors.

30. Thesis and Dissertation Advising/Post-doctoral student supervision:

2016: Currently mentoring pre-med UM student Nikhil Das.

2013- present: Mentored UM pre-med students, medical school students and Harrington program students.

2007: MPH Thesis: Dose dependent effects of alcohol on health. University of North Texas Health Science Center, Fort Worth, TX.

VII. Service:

31. University Committee and Administrative Responsibilities:

Miami Transplant Institute: Medical Director of Small Bowel/Multi-visceral Transplant
01/2013 – Present

32. Community Activities:

Sep 2015: Raising Hepatitis Awareness in India. Sardar Patel College, Hyderabad, India.

2005: Representative Delegate, Committee of Interns and Residents (CIR)